Search research articles
Contact Us
Filters
Showing results (131-140 of 141) with videos related to
Page
of 15
Sort By:
Thrombosis and Haemostasis
|
September 22, 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial
Alok A Khorana, Saroj Vadhan-Raj, Nicole M Kuderer, et al.
Journal of Hematology & Oncology
|
February 19, 2013
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
Ted Wun, Denis Soulieres, Andrew L Frelinger, et al.
JCO Oncology Practice
|
January 6, 2022
Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Urshila Durani, Ajay Major, Ana I Velazquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2003
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
Primo N Lara, David I Quinn, Kim Margolin, et al.
Transplantation and Cellular Therapy
|
November 19, 2023
Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018
Bryan Valcarcel, Sara J Schonfeld, Christa L Meyer, et al.
Leukemia Research
|
June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center
Tamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
Blood
|
August 18, 2022
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis
Carlton D Dampier, Marilyn Jo Telen, Ted Wun, et al.
Blood Advances
|
June 12, 2024
Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry
Sara J Schonfeld, Bryan Valcarcel, Christa L Meyer, et al.
The New England Journal of Medicine
|
February 21, 2019
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Alok A Khorana, Gerald A Soff, Ajay K Kakkar, et al.
Current Epidemiology Reports
|
September 13, 2023
Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults
Hazel B Nichols, Karen J Wernli, Neetu Chawla, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 141) with videos related to
Sort By:
Page
of 15
Thrombosis and Haemostasis
|
September 22, 2017
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial
Alok A Khorana, Saroj Vadhan-Raj, Nicole M Kuderer, et al.
Journal of Hematology & Oncology
|
February 19, 2013
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
Ted Wun, Denis Soulieres, Andrew L Frelinger, et al.
JCO Oncology Practice
|
January 6, 2022
Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
Urshila Durani, Ajay Major, Ana I Velazquez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2003
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
Primo N Lara, David I Quinn, Kim Margolin, et al.
Transplantation and Cellular Therapy
|
November 19, 2023
Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018
Bryan Valcarcel, Sara J Schonfeld, Christa L Meyer, et al.
Leukemia Research
|
June 23, 2022
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center
Tamer Othman, Benjamin N Moskoff, Gwendolyn Ho, et al.
Blood
|
August 18, 2022
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis
Carlton D Dampier, Marilyn Jo Telen, Ted Wun, et al.
Blood Advances
|
June 12, 2024
Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry
Sara J Schonfeld, Bryan Valcarcel, Christa L Meyer, et al.
The New England Journal of Medicine
|
February 21, 2019
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Alok A Khorana, Gerald A Soff, Ajay K Kakkar, et al.
Current Epidemiology Reports
|
September 13, 2023
Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults
Hazel B Nichols, Karen J Wernli, Neetu Chawla, et al.
Page
of 15